Efzimfotase alfa shows strong Phase III results in pediatric hypophosphatasia trial
The study also met its key secondary endpoint for bone health
The study also met its key secondary endpoint for bone health
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Subscribe To Our Newsletter & Stay Updated